Compare Stocks: ABVC, ICCC, ALDX, and HRTX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABVC ABVC BioPharma	$1.02 +1.0%	$1.34	$0.88 ▼ $3.40	$26.82M	0.57	116,168 shs	36,138 shs
ALDX Aldeyra Therapeutics	$1.59 -0.6%	$1.83	$1.07 ▼ $6.18	$96.51M	1.21	1.13 million shs	573,829 shs
HRTX Heron Therapeutics	$0.50 -1.1%	$0.46	$0.38 ▼ $1.86	$95.55M	1.65	2.15 million shs	1.71 million shs
ICCC ImmuCell	$11.02 +2.5%	$10.40	$4.52 ▼ $12.10	$97.25M	0.54	25,756 shs	41,567 shs

7 Stocks to Buy And Hold Forever

Click the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABVC ABVC BioPharma	-5.61%	0.00%	-46.84%	-8.18%	-66.33%
ALDX Aldeyra Therapeutics	+3.23%	-0.62%	-29.82%	-7.51%	-68.99%
HRTX Heron Therapeutics	-1.31%	+2.29%	+16.34%	-59.29%	-72.11%
ICCC ImmuCell	-2.89%	-2.36%	+6.86%	+26.92%	+74.23%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABVC ABVC BioPharma	$1.02 +1.0%	$1.34	$0.88 ▼ $3.40	$26.82M	0.57	116,168 shs	36,138 shs
ALDX Aldeyra Therapeutics	$1.59 -0.6%	$1.83	$1.07 ▼ $6.18	$96.51M	1.21	1.13 million shs	573,829 shs
HRTX Heron Therapeutics	$0.50 -1.1%	$0.46	$0.38 ▼ $1.86	$95.55M	1.65	2.15 million shs	1.71 million shs
ICCC ImmuCell	$11.02 +2.5%	$10.40	$4.52 ▼ $12.10	$97.25M	0.54	25,756 shs	41,567 shs

7 Stocks to Buy And Hold Forever

Click the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABVC ABVC BioPharma	-5.61%	0.00%	-46.84%	-8.18%	-66.33%
ALDX Aldeyra Therapeutics	+3.23%	-0.62%	-29.82%	-7.51%	-68.99%
HRTX Heron Therapeutics	-1.31%	+2.29%	+16.34%	-59.29%	-72.11%
ICCC ImmuCell	-2.89%	-2.36%	+6.86%	+26.92%	+74.23%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ABVC ABVC BioPharma	1.00	Sell	N/A	N/A
ALDX Aldeyra Therapeutics	2.00	Hold	$5.50	245.91% Upside
HRTX Heron Therapeutics	2.20	Hold	$2.50	401.00% Upside
ICCC ImmuCell	1.00	Sell	N/A	N/A

Current Analyst Ratings Breakdown

Latest ABVC, ICCC, ALDX, and HRTX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/3/2026	HRTX Heron Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold
7/17/2026	HRTX Heron Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/2/2026	ICCC ImmuCell	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
6/15/2026	ABVC ABVC BioPharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
6/3/2026	HRTX Heron Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$2.00
6/2/2026	HRTX Heron Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy ➝ Hold
5/29/2026	ABVC ABVC BioPharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
5/20/2026	ALDX Aldeyra Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
5/15/2026	ABVC ABVC BioPharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
5/11/2026	HRTX Heron Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy

(Data available from 8/6/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ABVC ABVC BioPharma	$510K	53.10	N/A	N/A	$0.52 per share	1.96
ALDX Aldeyra Therapeutics	N/A	N/A	N/A	N/A	$0.74 per share	N/A
HRTX Heron Therapeutics	$150.71M	0.63	N/A	N/A	$0.07 per share	7.13
ICCC ImmuCell	$27.64M	3.61	$0.20 per share	55.76	$2.99 per share	3.69

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ABVC ABVC BioPharma	-$7.91M	-$0.40	N/A	N/A	N/A	N/A	-62.46%	-39.99%	8/18/2026 (Estimated)
ALDX Aldeyra Therapeutics	-$33.85M	-$0.46	N/A	N/A	N/A	N/A	-57.34%	-36.33%	8/6/2026 (Estimated)
HRTX Heron Therapeutics	-$20.19M	-$0.18	N/A	N/A	N/A	-20.53%	-7,747.30%	-8.94%	8/10/2026 (Estimated)
ICCC ImmuCell	-$1.04M	-$0.06	N/A	N/A	N/A	-1.82%	-1.88%	-1.22%	8/13/2026 (Estimated)

Latest ABVC, ICCC, ALDX, and HRTX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/18/2026	Q2 2026	ABVC ABVC BioPharma	-$0.40	N/A	N/A	N/A	$0.11 million	N/A
8/13/2026	Q2 2026	ICCC ImmuCell	$0.05	N/A	N/A	N/A	$5.40 million	N/A
8/10/2026	Q2 2026	HRTX Heron Therapeutics	-$0.02	N/A	N/A	N/A	$42.19 million	N/A
8/6/2026	Q2 2026	ALDX Aldeyra Therapeutics	-$0.0775	-$0.09	-$0.0125	-$0.09	$31.33 million	N/A
5/18/2026	Q1 2026	ABVC ABVC BioPharma	N/A	-$0.06	N/A	-$0.06	N/A	N/A
5/14/2026	Q1 2026	ICCC ImmuCell	$0.05	$0.21	+$0.16	$0.21	$5.40 million	$10.36 million
5/11/2026	Q1 2026	HRTX Heron Therapeutics	-$0.03	-$0.04	-$0.01	-$0.04	$36.72 million	$34.71 million
5/7/2026	Q1 2026	ALDX Aldeyra Therapeutics	-$0.13	-$0.06	+$0.07	-$0.06	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ABVC ABVC BioPharma	N/A	N/A	N/A	N/A	N/A
ALDX Aldeyra Therapeutics	N/A	N/A	N/A	N/A	N/A
HRTX Heron Therapeutics	N/A	N/A	N/A	N/A	N/A
ICCC ImmuCell	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ABVC ABVC BioPharma	N/A	0.12	0.12
ALDX Aldeyra Therapeutics	N/A	2.72	2.72
HRTX Heron Therapeutics	17.51	2.53	1.51
ICCC ImmuCell	0.24	4.82	2.60

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ABVC ABVC BioPharma	11.38%
ALDX Aldeyra Therapeutics	59.71%
HRTX Heron Therapeutics	80.01%
ICCC ImmuCell	13.47%

Insider Ownership

Company	Insider Ownership
ABVC ABVC BioPharma	19.00%
ALDX Aldeyra Therapeutics	11.80%
HRTX Heron Therapeutics	6.10%
ICCC ImmuCell	5.70%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ABVC ABVC BioPharma	30	26.55 million	21.51 million	Not Optionable
ALDX Aldeyra Therapeutics	10	60.32 million	53.20 million	Optionable
HRTX Heron Therapeutics	300	189.28 million	177.73 million	Optionable
ICCC ImmuCell	70	9.05 million	8.53 million	Not Optionable

ABVC, ICCC, ALDX, and HRTX Headlines

Recent News About These Companies

ImmuCell to Announce Unaudited Financial Results for the Quarter Ended June 30, 2026

August 6 at 4:05 PM | globenewswire.com

ImmuCell (ICCC) Projected to Post Quarterly Earnings on Thursday

August 6 at 2:26 AM | americanbankingnews.com

ImmuCell (ICCC) Expected to Release Earnings on Thursday

August 6 at 2:25 AM | marketbeat.com

ImmuCell (NASDAQ:ICCC) Stock Price Passes Above 200-Day Moving Average - Here's Why

July 29, 2026 | marketbeat.com

ImmuCell: First Defense With Better Execution

July 24, 2026 | seekingalpha.com

ImmuCell (NASDAQ:ICCC) Stock Crosses Above 200 Day Moving Average - What's Next?

July 21, 2026 | marketbeat.com

ImmuCell posts strong preliminary Q2 sales on US demand

July 11, 2026 | msn.com

ImmuCell Posts Strong Preliminary Q2 Sales on U.S. Demand

July 10, 2026 | zacks.com

ImmuCell reports preliminary Q2 sales increase of 11.5% to $7.2M

July 9, 2026 | msn.com

ImmuCell Announces a 12% Increase in Product Sales in Q2 of 2026 and a 21% Increase in the First Six Months of 2026, Based on Preliminary, Unaudited Sales Results

July 9, 2026 | globenewswire.com

Insider Buying: ImmuCell (NASDAQ:ICCC) CEO Acquires $75,920.00 in Stock

June 23, 2026 | insidertrades.com

ICCC's Valuation Remains Premium: Is it Worth Overpaying for?

June 18, 2026 | zacks.com

ImmuCell Q1 Earnings Rise Y/Y as Sales Climb on Strong Demand

May 25, 2026 | zacks.com

ImmuCell (ICCC) Q1 2026 Earnings Transcript

May 17, 2026 | aol.comA

ImmuCell Corp (ICCC) Q1 2026 Earnings Call Highlights: Record Revenue and Strategic Growth

May 17, 2026 | finance.yahoo.com

ImmuCell Corporation (NASDAQ:ICCC) Q1 2026 Earnings Call Transcript

May 16, 2026 | insidermonkey.com

ImmuCell Corporation (ICCC) Q1 2026 Earnings Call Transcript

May 15, 2026 | seekingalpha.com

ImmuCell Announces Unaudited Financial Results for the Quarter Ended March 31, 2026

May 14, 2026 | globenewswire.com

Here’s Why ImmuCell Corporation (ICCC) is Emerging as an Intriguing Micro-Cap Opportunity

May 13, 2026 | insidermonkey.com

ImmuCell Reaches Settlement Agreement with Norbrook Laboratories

May 8, 2026 | tipranks.com

ImmuCell to Announce Unaudited Financial Results for the Quarter Ended March 31, 2026

May 7, 2026 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ABVC, ICCC, ALDX, and HRTX Company Descriptions

ABVC BioPharma NASDAQ:ABVC

$1.02 +0.01 (+0.99%)

Closing price 04:00 PM Eastern

Extended Trading

$1.02 +0.00 (+0.49%)

As of 06:30 PM Eastern

ABVC BioPharma, Inc., a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase II clinical trials a combination therapy for triple negative breast cancer; ABV-1504 has completed Phase II clinical trials for major depressive disorders; ABV-1505, which is in Phase II clinical trials for adult attention deficit hyperactivity disorder; ABV-1703, which is in Phase II clinical trials for the treatment of metastatic pancreatic cancer; ABV-1702, which is in Phase II clinical trials to treat myelodysplastic syndromes; and ABV-1601 that is in Phase I/II clinical trials for treating depression in cancer patients. It is also developing ABV-1701 Vitargus that is in Phase II clinical trials for the treatment of retinal detachment or vitreous hemorrhage; and ABV-1519, which is in Phase I/II clinical trials for the treatment of non-small cell lung cancer. ABVC BioPharma, Inc. has a co-development agreement with Rgene Corporation; and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation. The company is based in Fremont, California. ABVC BioPharma, Inc. operates as a subsidiary of YuanGene Corporation.

Aldeyra Therapeutics NASDAQ:ALDX

$1.59 -0.01 (-0.63%)

Closing price 04:00 PM Eastern

Extended Trading

$1.60 +0.00 (+0.31%)

As of 06:09 PM Eastern

Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company's lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A. Reproxalap is being evaluated in Phase 3 clinical trials in patients with dry eye disease and allergic conjunctivitis. The company's clinical pipeline also includes ADX-2191, a dihydrofolate reductase inhibitor in Phase 3 testing for proliferative vitreoretinopathy, and ADX-1612, a chaperome inhibitor in Phase 2 testing for COVID-19 and ovarian cancer.

Heron Therapeutics NASDAQ:HRTX

$0.50 -0.01 (-1.15%)

Closing price 04:00 PM Eastern

Extended Trading

$0.50 0.00 (-0.80%)

As of 06:50 PM Eastern

Heron Therapeutics, Inc., a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; and APONVIE, an intravenous formulation of a substance P/neurokinin-1 receptor antagonist indicated for the prevention of postoperative nausea and vomiting in adults. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in San Diego, California.

ImmuCell NASDAQ:ICCC

$11.02 +0.27 (+2.51%)

Closing price 04:00 PM Eastern

Extended Trading

$11.00 -0.01 (-0.14%)

As of 04:21 PM Eastern

ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. The company operates through two segments, Scours and Mastitis. It offers First Defense, an orally delivered scours preventive product for calves with claims against E. coli, coronavirus, and rotavirus; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. The company also provides California Mastitis Test, a quick on-farm diagnostic that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic; and Dual-Force First Defense, a bivalent gel tube formulation. In addition, it is developing Re-Tain Drug Product, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows. It sells its products through animal health distributors. ImmuCell Corporation was incorporated in 1982 and is headquartered in Portland, Maine.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ABVC, ICCC, ALDX, and HRTX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ABVC, ICCC, ALDX, and HRTX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ABVC, ICCC, ALDX, and HRTX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ABVC, ICCC, ALDX, and HRTX Company Descriptions

ABVC BioPharma NASDAQ:ABVC

Aldeyra Therapeutics NASDAQ:ALDX

Heron Therapeutics NASDAQ:HRTX

ImmuCell NASDAQ:ICCC

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ABVC, ICCC, ALDX, and HRTX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ABVC, ICCC, ALDX, and HRTX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ABVC, ICCC, ALDX, and HRTX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ABVC, ICCC, ALDX, and HRTX Company Descriptions

ABVC BioPharma NASDAQ:ABVC

Aldeyra Therapeutics NASDAQ:ALDX

Heron Therapeutics NASDAQ:HRTX

ImmuCell NASDAQ:ICCC

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools